This course takes stock of tuberculosis today and the challenges posed by drug resistance and therapeutic advances.
Tuberculosis has been a scourge of humanity for thousands of years. Today, of all infectious agents except SARS-Cov2, tuberculosis is still the biggest killer, surpassing even HIV and malaria. The global incidence is decreasing, but too slowly to achieve the goal of eventual eradication. This is partly because the disease takes months to develop and at least 6 months of multidrug chemotherapy to cure. In most people the infection becomes latent but can emerge decades later to cause serious illness. Over the past 3 decades, multidrug resistance has become an increasing problem, making TB even harder to cure.
At the end of this course, you will be able to:
- Describe the global epidemiology of TB, including M. africanum.
- Recognize different clinical forms of TB: subclinical, pediatric, HIV co-infections, meningitis, etc.
- Understand the best tests for diagnosing TB and detecting drug resistance.
- Appreciate the use of whole genome sequencing to define the phylogeny of TB, trace transmission chains and detect drug resistance.
- Describe the new drugs and best treatments and for drug-resistant TB and non-tuberculous mycobacterial infections.
- Discuss the immune response to TB infection and clinical trials of new vaccines.
Ce MOOC fait partie du Diplôme numérique de maladies infectieuses de l’Institut Pasteur DNM2IP.
Enrollment: From October 04, 2022 to January 23, 2023
Course: From December 06, 2022 to January 31, 2023
Languages: The videos are in English, with English and French subtitles.
More courses on: https://www.pasteur.fr/en/e-learning-mooc
Pôle d’enseignement Numérique